Concord Drugs Limited reported a consolidated net profit of ₹105.50 lakh for the financial year ended March 31, 2026, marking a substantial increase from ₹33.62 lakh in the previous year. Revenue from operations surged to ₹7,877.13 lakh, compared to ₹4,525.91 lakh in FY25, primarily driven by higher net sales. The company’s Board of Directors approved the standalone and consolidated financial results for the quarter and year ended March 31, 2026, at a meeting held on May 27, 2026.

Financial Performance

For the quarter ended March 31, 2026, the company reported a consolidated net profit of ₹52.80 lakh, up from ₹3.90 lakh in the corresponding period of the previous year. Net sales from operations for the quarter stood at ₹3,788.80 lakh, a significant rise from ₹1,039.17 lakh in Q4FY25. Total expenses for the year increased to ₹7,729.81 lakh from ₹4,456.77 lakh in the prior year, attributed to higher costs of material consumed and employee benefit expenses.

Capital Structure and Equity

During the quarter ended December 31, 2025, the company issued 31,75,000 equity shares at a price of ₹36.30 per share on a preferential basis. Additionally, 20,25,000 warrants were allotted at ₹36.30 per warrant, with 25% of the upfront amounting to ₹1,83,76,875 received during the period. Consequently, the paid-up equity share capital increased to ₹1,317.50 lakh as of March 31, 2026, from ₹1,000.00 lakh in the previous year.

Auditor’s Observations

Pundarikashyam and Associates, the statutory auditors, highlighted an emphasis of matter regarding long outstanding trade receivables of ₹4.14 crore in the books of accounts for more than two years, for which no provision for bad or doubtful debts has been made. The auditors also noted that balances of trade receivables, deposits, loans, advances, and trade payables are subject to confirmation from respective parties and consequential reconciliation or adjustment. Closing stocks are considered in the books based on management representation and are subject to verification.

Consolidated Financial Results

The following table summarizes the key financial metrics for the consolidated results for the year ended March 31, 2026:

The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013. The auditors confirmed that the results give a true and fair view of the company's financial performance.

Concord Drugs Limited has submitted its quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 to BSE Limited for the quarter ended March 31, 2026. The pharmaceutical company's Registrar and Share Transfer Agent, Aarthi Consultants Private Limited, issued the compliance certificate confirming adherence to dematerialization requirements during the period from January 1, 2026 to March 31, 2026.

Quarterly Compliance Certificate Details

The certificate was submitted by S Manoj Kumar Reddy, Whole Time Director (DIN: 06991382), on April 10, 2026, ensuring proper corporate authorization through digital signature. Aarthi Consultants Private Limited, serving as the Category I Registrars & Share Transfer Agents with SEBI Registration Number INR000000379, issued the compliance certificate on April 3, 2026.

Dematerialization Compliance Actions

Aarthi Consultants Private Limited confirmed completion of all required actions within 15 days of receiving certificates from depository participants for dematerialization purposes. The compliance actions included ensuring securities are listed on appropriate stock exchanges, mutilating and cancelling physical certificates forwarded by participants, and substituting the depository name as registered owner in company records.

Corporate Information and Authorization

Concord Drugs Limited, incorporated under CIN L24230TG1995PLC020093, maintains its registered office and factory at Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, with administrative operations at L B Nagar, Hyderabad. The company trades under scrip code 538965 on BSE Limited.

The quarterly certificate submission demonstrates Concord Drugs Limited's continued compliance with SEBI depositories regulations, ensuring proper handling of dematerialization processes through its appointed registrar and share transfer agent for the quarter ended March 31, 2026.